| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8236285 | AYTU | Buccal, polar and non-polar spray containing zolpidem |
Aug, 2032
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7632517 | AYTU | Buccal, polar and non-polar spray containing zolpidem |
Oct, 2017
(6 years ago) | |
Zolpimist is owned by Aytu.
Zolpimist contains Zolpidem Tartrate.
Zolpimist has a total of 2 drug patents out of which 1 drug patent has expired.
Expired drug patents of Zolpimist are:
- US7632517
Zolpimist was authorised for market use on 19 December, 2008.
Zolpimist is available in spray, metered;oral dosage forms.
Zolpimist can be used as treatment of transient insomnia.
The generics of Zolpimist are possible to be released after 07 August, 2032.
Drugs and Companies using ZOLPIDEM TARTRATE ingredient
Market Authorisation Date: 19 December, 2008
Treatment: Treatment of transient insomnia
Dosage: SPRAY, METERED;ORAL
More Information on Dosage
ZOLPIMIST family patents
